Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global hemoglobinopathies market size reached US$ 9.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.39% during 2023-2028.

Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.

Hemoglobinopathies Market Trends:

The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Hemoglobinopathies Market Trends:

The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Blood Transfusion

Stem-cell Transplantation

Analgesics

Antibiotics

ACE Inhibitors

Hydroxyurea

Others

Breakup by Test Type:

Red Blood Cell (RBC) Count

Genetic Testing

High Performance Liquid Chromatography (HPLC)

Hemoglobin Isoelectric Focusing (Hb IEF)

Hemoglobin Electrophoresis (Hb ELP)

Hemoglobin Solubility Test

Breakup by End User:

Hospitals and Clinics

Diagnostics Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.

Key Questions Answered in This Report

1. What was the size of the global hemoglobinopathies market in 2022?

2. What is the expected growth rate of the global hemoglobinopathies market during 2023-2028?

3. What has been the impact of COVID-19 on the global hemoglobinopathies market?

4. What are the key factors driving the global hemoglobinopathies market?

5. What is the breakup of the global hemoglobinopathies market based on the type?

6. What is the breakup of the global hemoglobinopathies market based on the treatment?

7. What are the key regions in the global hemoglobinopathies market?

8. Who are the key players/companies in the global hemoglobinopathies market?